PLX2853 BETi: ABT199 combination therapy enhances survival in DHL xenografts. After detection of tumor growth, SUDHL6- or OCI-LY8–bearing NSG animals were randomized into treatment arms with equivalent mean tumor volume. Subsequently, animals were treated with 5 mg/kg PLX2853 (orally once daily), 50 mg/kg ABT199 (orally once daily), or both in combination, and tumor growth was monitored in comparison with a vehicle control (A-B). Animals were maintained on therapy until the humane end point was reached (OCI-LY8) or for 28 days (SUDHL6), and overall survival was assessed (C). Shaded area in panel B represents tumor size before start of treatment. OCI-LY8 data represent 2 independent experiments combined: vehicle (n = 14), ABT199 (n = 12), PLX2853 (n = 12), combination (n = 9). SUDHL6 data: vehicle (n = 6), ABT199 (n = 4), PLX2853 (n = 5), combination (n = 6). (A-B) Statistical analyses were performed using 2-way ANOVA and Dunnett’s multiple comparisons test. (C) Survival analysis was performed using a log-rank test and Holm-Sidak multiple comparisons correction. Error bars represent SEM. ****P < .00005, ***P < .0005, **P < .005, *P > .05.